SHP2 phosphatase inhibitors and methods of use thereof
Alexander M. Taylor, Cambridge, MA (US); André Lescarbeau, Somerville, MA (US); Elizabeth H. Kelley, Cambridge, MA (US); Kelley C. Shortsleeves, Maynard, MA (US); W. Patrick Walters, Westborough, MA (US); Mark Andrew Murcko, Holliston, MA (US); Thomas H. McLean, West Roxbury, MA (US); Hakan Gunaydin, Somerville, MA (US); Fabrizio Giordanetto, New York, NY (US); and Eric Therrien, Bronx, NY (US)
Assigned to Relay Therapeutics, Inc., Cambridge, MA (US)
Filed by Relay Therapeutics, Inc., Cambridge, MA (US); and D. E. Shaw Research, LLC, New York, NY (US)
Filed on Nov. 17, 2020, as Appl. No. 16/950,576.
Application 16/950,576 is a continuation of application No. 16/886,105, filed on May 28, 2020, granted, now 10,934,302.
Application 16/886,105 is a continuation of application No. PCT/US2019/023389, filed on Mar. 21, 2019.
Claims priority of provisional application 62/737,819, filed on Sep. 27, 2018.
Claims priority of provisional application 62/661,902, filed on Apr. 24, 2018.
Claims priority of provisional application 62/649,834, filed on Mar. 29, 2018.
Claims priority of provisional application 62/646,083, filed on Mar. 21, 2018.
Claims priority of provisional application 62/646,099, filed on Mar. 21, 2018.
Prior Publication US 2022/0340576 A1, Oct. 27, 2022
1. A method of treating a SHP2-mediated cancer, the method comprising administering to a human subject having said cancer an effective amount of a compound selected from the group consisting of:
